Spyre Therapeutics Ownership | Who Owns Spyre Therapeutics?


OverviewForecastFinancialsChart

Spyre Therapeutics Ownership Summary


Spyre Therapeutics is owned by 102.13% institutional investors, 6.72% insiders. Fmr is the largest institutional shareholder, holding 14.93% of SYRE shares.

SYRE Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSpyre Therapeutics102.13%6.72%-8.85%
SectorHealthcare Stocks 42.51%10.81%46.68%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr9.06M14.93%$151.85M
Fairmount funds management4.02M6.62%$67.34M
Blackrock funding, inc. /de3.98M6.56%$66.75M
Rtw investments, lp3.62M5.97%$60.70M
Tang capital management3.20M5.27%$53.63M
Vanguard group3.05M5.03%$51.13M
Vr adviser2.69M4.42%$45.01M
Braidwell lp2.58M4.25%$43.21M
Capital investors2.39M3.94%$40.10M
Driehaus capital management2.06M3.39%$34.53M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Fairmount funds management4.02M6.06%$67.34M
Vr adviser2.69M2.53%$45.01M
Affinity asset advisors1.42M2.07%$23.79M
Tang capital management3.20M2.06%$53.63M
Commodore capital lp1.99M1.63%$33.32M
Braidwell lp2.58M1.28%$43.21M
B group100.00K1.23%$1.68M
Boxer capital696.48K1.01%$20.48M
Tcg crossover management1.10M0.91%$18.45M
Highvista strategies215.75K0.89%$3.62M

Top Buyers

HolderShares% AssetsChange
Tcg crossover management1.10M0.91%1.10M
Affinity asset advisors1.42M2.07%812.62K
Baker bros. advisors lp1.00M0.12%373.30K
Janus henderson group1.46M0.02%336.21K
Jpmorgan chase275.98K0.00%228.71K

Top Sellers

HolderShares% AssetsChange
Farallon capital management---666.00K
Adage capital partners gp---610.20K
Avoro capital advisors---598.60K
Logos global management lp---500.00K
First turn management---464.44K

New Positions

HolderShares% AssetsChangeValue
Tcg crossover management1.10M0.91%1.10M$18.45M
Parkman healthcare partners200.75K0.35%200.75K$3.36M
Jane street group96.06K0.00%96.06K$1.61B
Dimensional fund advisors lp84.22K0.00%84.22K$1.41M
Schonfeld strategic advisors81.47K0.01%81.47K$1.37M

Sold Out

HolderChange
National bank of canada /fi/-1.00
Amundi-5.00
Pacific capital wealth advisors-8.00
Parallel advisors-14.00
True wealth design-16.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20251321.54%61,991,182-2.57%1020.93%62-25.30%4268.00%
Jun 30, 2025129-1.53%63,612,5039.51%10437.19%8110.96%26-23.53%
Mar 31, 20251320.76%62,108,0533.71%170.13%73-23.96%3478.95%
Dec 31, 2024120-50,788,525-1.15%990.78%8619.44%18-25.00%
Sep 30, 202455-49.07%19,042,524-62.21%420.34%42-44.00%5-70.59%

Recent Insider Transactions


DateNameRoleActivityValue
Dec 01, 2025Turtle Cameron Chief Executive OfficerSell$119.47K
Dec 01, 2025Turtle Cameron Chief Executive OfficerSell$315.89K
Nov 03, 2025Turtle Cameron Chief Executive OfficerSell$651.23K
Nov 03, 2025Turtle Cameron Chief Executive OfficerSell$398.55K
Sep 02, 2025Burrows Scott L Chief Financial OfficerSell$299.64K

Insider Transactions Trends


DateBuySell
2025 Q3-1
2025 Q2--
2025 Q1--
2024 Q4-2
2024 Q3-1

SYRE Ownership FAQ


Who Owns Spyre Therapeutics?

Spyre Therapeutics shareholders are primarily institutional investors at 102.13%, followed by 6.72% insiders and -8.85% retail investors. The average institutional ownership in Spyre Therapeutics's industry, Biotech Stocks , is 45.22%, which Spyre Therapeutics exceeds.

Who owns the most shares of Spyre Therapeutics?

Spyre Therapeutics’s largest shareholders are Fmr (9.06M shares, 14.93%), Fairmount funds management (4.02M shares, 6.62%), and Blackrock funding, inc. /de (3.98M shares, 6.56%). Together, they hold 28.11% of Spyre Therapeutics’s total shares outstanding.

Does Blackrock own Spyre Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Spyre Therapeutics.

Who is Spyre Therapeutics’s biggest shareholder by percentage of total assets invested?

Fairmount funds management is Spyre Therapeutics’s biggest shareholder by percentage of total assets invested, with 6.06% of its assets in 4.02M Spyre Therapeutics shares, valued at 67.34M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools